Streetbeat News

Analyst Ratings

WPM

In the last 3 months, 4 analysts have provided 12-month price targets for Wheaton Precious Metals (NYSE:WPM), with an average target of $49.75. The average price target has increased by 5.85% over the past month.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 4:04 pm

ANIX

In the last quarter, Anixa Biosciences (NASDAQ:ANIX) received 6 bullish analyst ratings. The average 12-month price target for the stock is $10.83, up 14% from the previous average of $9.50.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 4:03 pm

CRM

A large bearish position on Salesforce (NYSE:CRM) has been spotted, with 72% of big-money traders showing bearish sentiment. Whales have been targeting a price range of $65.0 to $237.5 for Salesforce over the last 3 months.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 4:02 pm

PACW

Over the past 3 months, 9 analysts have published their opinion on PacWest Banc (NASDAQ:PACW) stock, with an average 12-month price target of $18.44. The current average has decreased by 15.65% from the previous average price target of $21.86.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 4:01 pm

TPVG

Over the past 3 months, 6 analysts have published their opinion on TriplePoint Venture Gwth (NYSE:TPVG) stock, with an average 12-month price target of $12.33, down 8.67% from the previous average of $13.50.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 4:00 pm

MEIP

Brookline Capital has reiterated its Buy rating for MEI Pharma, maintaining an $80 price target.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:47 pm

MTCH

Match Group shares are being closely watched as positive comments from the JP Morgan Conference circulate among traders.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:45 pm

STOK

Stoke Therapeutics shares are trading higher after Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $20 to $25.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:43 pm

IOVA

Iovance Biotherapeutics shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:41 pm